China boosts medical insurance spending on innovative drugs
Share - WeChat
BEIJING -- During the 14th Five-Year Plan period (2021-2025), China's medical insurance spending on drugs newly included in the negotiations list, or the innovative drugs, grew significantly, increasing by 40 percent annually, an official from the National Healthcare Security Administration said on Thursday.
In 2024, related spending reached 3.9 times the amount recorded in 2020, Zhang Ke, head of the administration, told a press conference.
During this period, medical insurance fund expenditures totaled 12.13 trillion yuan (about $1.7 trillion), growing at an average annual rate of 9.1 percent, Zhang said.
- 'We can manage for now': HK rallies with fire recovery efforts on track
- Foreign media urged to report truthfully on HK matters
- Lee: Vote to drive reform and help HK fire victims
- SOEs do their part in HKSAR's post-fire recovery
- China releases new insurance-covered medicine list
- Voting kicks off in Hong Kong's LegCo election






























